Unicycive Therapeutics, Inc. (UNCY)

$5.09

USD

0.12(-2.30%)

At close: Jul 13, 18:21 EDT

Recently from Cashu

Unicycive Therapeutics Faces Turbulent Times

Unicycive Therapeutics, Inc. ( UNCY ) has recently come under intense scrutiny as it navigates significant challenges following a second Complete Response Letter from the FDA. This has sparked a wave…

Cashu Markets·7h ago

Open

$5.81

Prev. Close

$5.26

High

$5.91

Low

$5.31

Company Profile

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

CEOShalabh K. Gupta

SectorHealthcare

IndustryBiotechnology

Employees22

IPO DateJul 12, 2021

ExchangeNASDAQ

Exchange NameNASDAQ Capital Market

CurrencyUSD

Headquarters & Contact

Address4300 El Camino Real

City / State / ZIPLos Altos, CA, 94022

CountryUnited States

Phone650 351 4495

Websitehttps://www.unicycive.com